Abiopharma

🔍 Martin Christine M (Executive)

Company: PPL Corp (PPL)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Acquired 1,212 shares of Common Stock at $34.47 per share (Direct)
  Date: 2026-09-01 | Code: M | equity_swap_involved: false | shares_owned_after: 47,948.47 | transaction_form_type: 4 | Footnotes: F1
• Sold 346 shares of Common Stock at $34.47 per share (Direct)
  Date: 2026-09-01 | Code: F | equity_swap_involved: false | shares_owned_after: 47,602.47 | transaction_form_type: 4 | Footnotes: F2, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-09-01 | Code: H | nature_of_ownership: Held in trust pursuant to the Employee Stock Ownership Plan. | shares_owned_after: 248.86 | Footnotes: F1
• Sold 1,212 shares of Stock Unit (SIP) (Derivative)
  Date: 2026-09-01 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F3

Footnotes:

• F1: Total includes the reinvestment of dividends.
• F2: Shares withheld by the company at the request of the executive officer to pay taxes due following expiration of the applicable restriction period, under the terms of the Stock Incentive Plan (SIP) for Restricted Stock Units granted on 09/01/2023.
• F3: No conversion or exercise price or exercise or expiration date applies. The units vested on 09/01/2026.